Nov 2, 4:11 PM ET
Neurocrine Biosciences reported third-quarter 2026 total revenues of $1.1 billion, representing 41% year-over-year growth, alongside GAAP net income of $207 million. The company also raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion.
- Total revenues for the third quarter of 2026 reached $1.1 billion, up 41% compared to $795 million in the third quarter of 2025.
- INGREZZA net product sales were $801 million, leading management to raise full-year 2026 INGREZZA net sales guidance to $2.9 billion to $2.925 billion.
- GAAP net income for the third quarter of 2026 was $207 million, or $1.96 per diluted share, compared to $210 million, or $2.04 per diluted share, in the prior-year period.
Read the filing on SEC.gov ↗
Sep 28, 4:20 PM ET
Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. The filing says Dr. Roberts will receive a base salary of $825,000, a target bonus of 60% of base pay, and about $1.25 million in target equity grants, and that Dr. Keswani will receive severance under the company's Executive Severance Plan.
- Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
- Dr. Roberts was appointed Chief Medical Officer effective September 28, 2026, with an annual base salary of $825,000 and a target bonus of 60% of base pay for 2026.
- Target equity grants total about $1.25 million: stock options of about $625,000, restricted stock units of about $250,000, and performance-vesting restricted stock units of about $375,000.
- The final Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Read the filing on SEC.gov ↗
Jul 30, 4:02 PM ET
Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% from $688 million a year earlier, with GAAP diluted earnings per share of $1.39 versus $1.06. The company raised its full-year 2026 INGREZZA net sales guidance to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion, and it completed its Soleno Therapeutics acquisition in May 2026.
- Total revenue was $959 million in Q2 2026 versus $688 million in Q2 2025.
- GAAP net income was $144 million, or $1.39 per diluted share, versus $108 million, or $1.06, a year earlier.
- INGREZZA full-year 2026 net product sales guidance was raised to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion.
- VYKAT XR net product sales were $54 million from May 18, 2026, the Soleno acquisition closing date.
Read the filing on SEC.gov ↗
May 28, 4:01 PM ET
At its annual meeting on May 27, 2026, Neurocrine Biosciences stockholders elected three Class III directors to three-year terms expiring at the 2029 meeting. They also approved an amendment to the 2025 Equity Incentive Plan, approved the compensation of named executive officers on an advisory basis, and ratified Ernst & Young LLP as the independent auditor for fiscal 2026. The plan amendment governs equity awards to employees and directors, and its material terms are described in the April 15, 2026 proxy statement.
- Shares present were 90,118,625 of 100,581,991 entitled to vote as of the March 31, 2026 record date.
- Amended 2025 Plan approved with 79,131,622 votes for, 5,568,926 against and 65,732 abstentions.
- Advisory vote on executive pay passed with 78,993,894 votes for and 5,669,155 against.
- Kevin C. Gorman, Ph.D. received 76,228,063 votes for; Gary A. Lyons received 75,278,705 and Johanna Mercier received 74,671,942.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.